Stockreport

Bolt Biotherapeutics to Present Data from Phase 1 Dose-Escalation Clinical Study of BDC-3042 at AACR Annual Meeting 2025 [Yahoo! Finance]

Bolt Biotherapeutics, Inc.  (BOLT) 
PDF novel immunotherapies for the treatment of cancer, today announced it will present data from the Phase 1 dose-escalation clinical study of BDC-3042 in patients with adva [Read more]